NO20072366L - Anti-glypikan antistoff med modifisert sukkerkjede - Google Patents

Anti-glypikan antistoff med modifisert sukkerkjede

Info

Publication number
NO20072366L
NO20072366L NO20072366A NO20072366A NO20072366L NO 20072366 L NO20072366 L NO 20072366L NO 20072366 A NO20072366 A NO 20072366A NO 20072366 A NO20072366 A NO 20072366A NO 20072366 L NO20072366 L NO 20072366L
Authority
NO
Norway
Prior art keywords
glypican
antibody
modified sugar
sugar chain
fucose
Prior art date
Application number
NO20072366A
Other languages
English (en)
Norwegian (no)
Inventor
Kiyotaka Nakano
Megumi Tanaka
Izumi Sugo
Takahiro Ishiguro
Masamichi Sugimoto
Shigeyuki Iijima
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20072366L publication Critical patent/NO20072366L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
NO20072366A 2004-10-26 2007-05-09 Anti-glypikan antistoff med modifisert sukkerkjede NO20072366L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004311356 2004-10-26
PCT/JP2005/020057 WO2006046751A1 (ja) 2004-10-26 2005-10-26 糖鎖改変抗グリピカン３抗体

Publications (1)

Publication Number Publication Date
NO20072366L true NO20072366L (no) 2007-06-21

Family

ID=36227980

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072366A NO20072366L (no) 2004-10-26 2007-05-09 Anti-glypikan antistoff med modifisert sukkerkjede

Country Status (20)

Country Link
US (2) US7867734B2 (ja)
EP (1) EP1816140A4 (ja)
JP (1) JP4794457B2 (ja)
KR (1) KR101296931B1 (ja)
CN (1) CN101068836B (ja)
AU (1) AU2005297772B2 (ja)
BR (1) BRPI0518279A2 (ja)
CA (1) CA2585196C (ja)
CR (1) CR9151A (ja)
HK (1) HK1110335A1 (ja)
IL (1) IL182662A (ja)
MA (1) MA29025B1 (ja)
MX (1) MX2007004593A (ja)
NO (1) NO20072366L (ja)
NZ (1) NZ554940A (ja)
RU (1) RU2451030C2 (ja)
TW (1) TWI468514B (ja)
UA (1) UA93488C2 (ja)
WO (1) WO2006046751A1 (ja)
ZA (1) ZA200703888B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
EP2228445A1 (en) * 2003-06-18 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Fucose Transporter
DE602005024502D1 (de) * 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
CN102698267B (zh) * 2004-08-24 2017-07-21 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法
EP1816140A4 (en) * 2004-10-26 2009-09-02 Chugai Pharmaceutical Co Ltd ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
AU2008275985B2 (en) * 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
WO2009041062A1 (ja) * 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 血漿中動態が改善されたグリピカン３抗体
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US8583781B2 (en) 2009-01-28 2013-11-12 Headwater Partners I Llc Simplified service network architecture
US8589541B2 (en) 2009-01-28 2013-11-19 Headwater Partners I Llc Device-assisted services for protecting network capacity
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US10889842B2 (en) * 2014-01-16 2021-01-12 Calysta, Inc. Microorganisms for the enhanced production of amino acids and related methods
AR100353A1 (es) 2014-05-08 2016-09-28 Chugai Pharmaceutical Co Ltd Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
WO2017020812A1 (zh) * 2015-08-03 2017-02-09 科济生物医药（上海）有限公司 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
BR112018015259A2 (pt) 2016-01-27 2018-12-18 Medimmune Llc métodos para preparação de anticorpos com um padrão de glicosilação definido
US11767362B1 (en) 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
WO2018019772A1 (en) 2016-07-26 2018-02-01 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
JP7125347B2 (ja) 2016-08-22 2022-08-24 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
CN106591371A (zh) * 2016-11-25 2017-04-26 哈尔滨百伊生生物科技有限公司 Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
EP3684413A1 (en) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
MX2021003744A (es) 2018-10-01 2021-06-23 Adicet Bio Inc Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos.
JP2022514262A (ja) 2018-12-17 2022-02-10 レビトープ リミテッド 双子型免疫細胞エンゲージャー
KR20220016452A (ko) * 2019-05-24 2022-02-09 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 항-csf1r 항체, il10 융합 단백질, 및 이들의 이용
EP4023230A4 (en) 2019-06-05 2023-11-15 Chugai Seiyaku Kabushiki Kaisha ANTIBODY CLEAVAGE SITE BINDING MOLECULE
WO2022171100A1 (zh) * 2021-02-10 2022-08-18 江苏先声药业有限公司 Gpc3人源化抗体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0242355A (ja) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd 超音波検査装置
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
HUP0001136A3 (en) * 1997-02-12 2002-02-28 Chugai Pharmaceutical Co Ltd Remedies for lymphocytic tumors
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US7052873B2 (en) * 1997-10-03 2006-05-30 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK2270147T4 (da) * 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
CN1234769C (zh) 2000-09-12 2006-01-04 联合碳化化学及塑料技术公司 含有烯化氧共聚物的聚合物复合材料
ES2651952T3 (es) 2000-10-06 2018-01-30 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
JP4336051B2 (ja) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信端末、発呼制限方法及びプログラム
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
DE60237929D1 (de) * 2001-06-22 2010-11-18 Chugai Pharmaceutical Co Ltd Zellproliferationshemmer, die Anti-Glypican 3 Antikörper enthalten
EP1423510A4 (en) * 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
CN100460872C (zh) * 2001-11-14 2009-02-11 株式会社东芝 超声波成像装置
EP3604523A1 (en) * 2001-12-28 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
BRPI0311233B8 (pt) * 2002-05-23 2021-07-27 Sunnybrook And Womens College Health Sciences Centre métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JPWO2005023301A1 (ja) * 2003-09-04 2006-11-02 中外製薬株式会社 胆管癌治療剤および検出薬
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
DE602005024502D1 (de) * 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
ATE484288T1 (de) * 2004-08-08 2010-10-15 Eli Khayat Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern
AU2005277567A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
CN102698267B (zh) * 2004-08-24 2017-07-21 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法
EP1816140A4 (en) 2004-10-26 2009-09-02 Chugai Pharmaceutical Co Ltd ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
BRPI0909672B1 (pt) * 2008-03-17 2018-09-18 Chugai Pharmaceutical Co Ltd método de imunoensaio in vitro para detecção da presença de células de câncer de fígado em um indivíduo, método para classificação de células de câncer de fígado presentes em um indivíduo, método in vitro para determinação de administrar ou não um agente anticâncer contendo um anticorpo anti-glipicano 3 a um indivíduo, e método in vitro para determinação de uma dose de um agente anticâncer contendo um anticorpo anti-glipicano 3 no tratamento de câncer de fígado em um indivíduo
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
WO2006046751A1 (ja) 2006-05-04
ZA200703888B (en) 2009-11-25
AU2005297772A1 (en) 2006-05-04
IL182662A (en) 2014-09-30
BRPI0518279A2 (pt) 2008-11-11
EP1816140A1 (en) 2007-08-08
KR20070070222A (ko) 2007-07-03
HK1110335A1 (en) 2008-07-11
CN101068836A (zh) 2007-11-07
TWI468514B (zh) 2015-01-11
CR9151A (es) 2008-03-18
JP4794457B2 (ja) 2011-10-19
US20110033452A1 (en) 2011-02-10
AU2005297772B2 (en) 2011-06-23
CN101068836B (zh) 2013-08-14
MA29025B1 (fr) 2007-11-01
KR101296931B1 (ko) 2013-08-14
TW200621980A (en) 2006-07-01
IL182662A0 (en) 2007-09-20
RU2451030C2 (ru) 2012-05-20
CA2585196A1 (en) 2006-05-04
EP1816140A4 (en) 2009-09-02
US7867734B2 (en) 2011-01-11
US20080124330A1 (en) 2008-05-29
CA2585196C (en) 2015-01-06
JPWO2006046751A1 (ja) 2008-05-22
NZ554940A (en) 2010-04-30
RU2007119579A (ru) 2008-12-10
UA93488C2 (uk) 2011-02-25
MX2007004593A (es) 2007-06-22

Similar Documents

Publication Publication Date Title
NO20072366L (no) Anti-glypikan antistoff med modifisert sukkerkjede
WO2009080743A3 (en) Plants with increased yield (ko nue)
WO2004065546A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1
WO2004078950A3 (en) METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
WO2007024718A3 (en) Genetically modified host cells and use of same for producing isoprenoid compounds
DK1546174T3 (da) Fremgangsmåder og sammensætninger til RNA-interferens
WO2005095618A3 (en) Plants with reduced activity of the starch phosphorylating enzyme phosphoglucan, water dikinase
NO20061673L (no) Modulering av EIF4E-ekspresjon
DE602004012881D1 (en) Cst (compartmentalised self tagging)
WO2007027509A3 (en) Evaluating and treating scleroderma
MX2007002382A (es) Producci??n de anticuerpos anti-amiloides beta.
RU2009145502A (ru) Одноцепочечная кольцевая рнк и способ ее получения
WO2011005860A3 (en) 5' phosphate mimics
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
BR112012012100A2 (pt) método para o tratamento de água dentro um reator biológico sequencial incluindo uma medição em linha da concentração de nitrito dentro do referido reator
NO20075865L (no) Innelukket behandlingskjemikalie og fremgangsmate for forsinket frigivelse av samme
WO2005090572A3 (en) Compositions and methods for treating pancreatic cancer
WO2006022664A3 (en) Alanine 2, 3 aminomutases
WO2005033287A3 (en) Methods for identifying a biosynthetic pathway gene product
WO2007089732A3 (en) Improvement of levels and/or sustainability of dna-based gene expression
WO2006066184A3 (en) Methods and compositions for ultra-high throughput screening of natural products
WO2006086681A3 (en) Methods of inhibiting smooth muscle cell migration and proliferation
WO2007071578A3 (de) Verfahren zur herstellung von 5 -norbornen-2-carbonsäure aus 5-norbornen-2-carbonitril unter verwendung einer arylacetonitrilase
WO2004089386A8 (ja) 消化酵素に対する鶏卵抗体を用いた抗肥満剤
WO2002095011A3 (de) Inaktivierung von genen des mep-wegs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application